Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
8 evidence topics · 11 sources
Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 serum levels were dose proportional and indicative of a PK profile with high exposure and long half‐life at higher doses, consistent with the expected effects of the YTE substitutions (Figure 4A and Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean terminal phase half‐life increased from 15 days at 0.3 mg/kg to 32 days at 9 mg/kg, which exceeds the average expected half‐life of 10–21 days for human IgG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results indicate a PK profile and volume of distribution consistent with those of a monoclonal antibody through this dosing range with evidence of target mediated clearance below approximately 5 μg/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the terminal half‐life of CDX‐0159 at a single 3 mg/kg dose was 23 days and was accompanied with tryptase suppression for >6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthy volunteers, single subcutaneous doses of 50 to 600 mg
Subcutaneous bioavailability, time to peak concentration, and half-life
No evidence found.
Nonclinical pharmacokinetics in cynomolgus macaques: effect of the YTE substitutions
“Consistent with previously published data with antibodies harboring YTE mutations, the pharmacokinetic properties of CDX‐0159 in cynomolgus macaques were indeed enhanced relative to CDX‐0158” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“terminal half‐life (22 ± 5.8 vs. 4.8 ± 3.5 days)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSU, multiple doses: dose-linear exposure, accumulation, and target saturation
“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic inducible urticaria, single 3 mg/kg intravenous dose: clearance, half-life, volume of distribution, and time to clearance
“Barzolvolimab pharmacokinetics in patients with CIndU (N = 20) following a single 3 mg/kg intravenous dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug levels reach approximately 1 μg/mL by Week 12, as MC markers and clinical symptoms start to recover.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab is fully cleared after Week 18.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prurigo nodularis, single intravenous dose: terminal half-life and exposure by sex, weight, and antidrug antibody status
CSU: barzolvolimab concentrations during the 24-week follow-up period of the phase 2 trial
Immunogenicity: treatment-emergent antidrug antibodies and their effect on exposure and safety
“The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity in the phase 2 and phase 3 CSU trials
No evidence found.